BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
BlossomHill Therapeutics announced its third-quarter 2026 financial results, highlighting FDA alignment on the Phase 2 dose for its lead candidate, BH-30643, and the initiation of the pivotal SOLARA-2 trial.